Healthcare provider profile · identity verified

Thanh N Vu, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SCOTTS VALLEY, CA · NPI 1396711149

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Thanh N Vu, MD received $67.01 in general payments during 2025 across 3 reported records.

Dompe US, Inc. accounted for 42.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$67.01

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Dompe US, Inc.	Unresolved — no canonical attribution shown	$28.63	42.7%	1	2025
Biogen, Inc.	Unresolved — no canonical attribution shown	$21.28	31.8%	1	2025
Edwards Lifesciences Corporation	Unresolved — no canonical attribution shown	$17.10	25.5%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$67.01	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
OXERVATE Normalized: oxervate	Drug	Dompe US, Inc.	$28.63	1	2025
Source payment records 2025-07-17 · Dompe US, Inc. · $28.63 · Open Payments source
ZURZUVAE Normalized: zurzuvae	Drug	Biogen, Inc.	$21.28	1	2025
Source payment records 2025-06-25 · Biogen, Inc. · $21.28 · Open Payments source
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve	Device	Edwards Lifesciences Corporation	$17.10	1	2025
Source payment records 2025-01-27 · Edwards Lifesciences Corporation · $17.10 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	503	106
Atorvastatin Calcium	Atorvastatin Calcium	429	119
Sertraline Hcl	Sertraline Hcl	370	65
Amlodipine Besylate	Amlodipine Besylate	346	95
Losartan Potassium	Losartan Potassium	323	87
Gabapentin	Gabapentin	296	86
Rosuvastatin Calcium	Rosuvastatin Calcium	291	81
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	260	62
Omeprazole	Omeprazole	209	58
Eliquis	Apixaban	208	41
Celecoxib	Celecoxib	205	50
Lorazepam	Lorazepam	204	54
Alprazolam	Alprazolam	198	51
Metoprolol Succinate	Metoprolol Succinate	198	53
Quetiapine Fumarate	Quetiapine Fumarate	183	29
Trazodone Hcl	Trazodone Hcl	172	49
Prednisone	Prednisone	171	71
Zolpidem Tartrate	Zolpidem Tartrate	168	39
Lisinopril	Lisinopril	140	38
Azithromycin	Azithromycin	130	92
Atenolol	Atenolol	128	32
Torsemide	Torsemide	128	35
Tamsulosin Hcl	Tamsulosin Hcl	126	35
Duloxetine Hcl	Duloxetine Hcl	120	28
Escitalopram Oxalate	Escitalopram Oxalate	118	33
Metoprolol Tartrate	Metoprolol Tartrate	115	21
Valsartan	Valsartan	113	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	112	32
Citalopram Hbr	Citalopram Hydrobromide	108	18
Donepezil Hcl	Donepezil Hcl	108	19
Valacyclovir	Valacyclovir Hcl	106	38
Furosemide	Furosemide	97	32
Tramadol Hcl	Tramadol Hcl	95	22
Mupirocin	Mupirocin	92	46
Clopidogrel	Clopidogrel Bisulfate	91	20
Metformin Hcl Er	Metformin Hcl	89	28
Memantine Hcl	Memantine Hcl	88	16
Allopurinol	Allopurinol	85	27
Simvastatin	Simvastatin	84	25
Meloxicam	Meloxicam	83	35
Montelukast Sodium	Montelukast Sodium	81	22
Pregabalin	Pregabalin	80	14
Spironolactone	Spironolactone	80	19
Pantoprazole Sodium	Pantoprazole Sodium	78	27
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	77	59
Ezetimibe	Ezetimibe	77	23
Potassium Chloride	Potassium Chloride	77	19
Triamcinolone Acetonide	Triamcinolone Acetonide	76	30
Ozempic	Semaglutide	71	12
Fluoxetine Hcl	Fluoxetine Hcl	68	16
Venlafaxine Hcl Er	Venlafaxine Hcl	68	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	67	48
Diazepam	Diazepam	66	18
Metformin Hcl	Metformin Hcl	65	19
Synthroid	Levothyroxine Sodium	64	16
Oxycodone Hcl	Oxycodone Hcl	62	19
Nystatin	Nystatin	61	30
Hydrochlorothiazide	Hydrochlorothiazide	60	18
Albuterol Sulfate Hfa	Albuterol Sulfate	57	32
Glipizide Er	Glipizide	57	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	57	14
Pravastatin Sodium	Pravastatin Sodium	56	16
Carvedilol	Carvedilol	54	14
Cephalexin	Cephalexin	54	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	54	12
Doxycycline Hyclate	Doxycycline Hyclate	53	35
Mirtazapine	Mirtazapine	53	14
Famotidine	Famotidine	52	16
Cefdinir	Cefdinir	50	38
Jardiance	Empagliflozin	49	suppressed
Diclofenac Sodium	Diclofenac Sodium	48	17
Latanoprost	Latanoprost	48	suppressed
Finasteride	Finasteride	47	11
Bupropion Hcl Sr	Bupropion Hcl	42	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	41	31
Ibuprofen	Ibuprofen	38	11
Fluticasone Propionate	Fluticasone Propionate	37	11
Glimepiride	Glimepiride	36	suppressed
Ketoconazole	Ketoconazole	36	14
Colchicine	Colchicine	35	11
Lactulose	Lactulose	35	18
Ibandronate Sodium	Ibandronate Sodium	34	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	14
Digoxin	Digoxin	33	suppressed
Levofloxacin	Levofloxacin	33	24
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	32	suppressed
Ondansetron Odt	Ondansetron	32	16
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	32	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	12
Trulicity	Dulaglutide	31	suppressed
Estradiol	Estradiol	29	13
Glipizide	Glipizide	29	suppressed
Myrbetriq	Mirabegron	29	suppressed
Baclofen	Baclofen	28	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	28	suppressed
Midodrine Hcl	Midodrine Hcl	28	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	28	suppressed
Acyclovir	Acyclovir	27	11
Paxlovid	Nirmatrelvir/Ritonavir	27	26
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Amoxicillin	Amoxicillin	26	18
Clonazepam	Clonazepam	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Temazepam	Temazepam	23	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Xarelto	Rivaroxaban	21	suppressed
Liothyronine Sodium	Liothyronine Sodium	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Testosterone	Testosterone	20	suppressed
Aripiprazole	Aripiprazole	19	suppressed
Flecainide Acetate	Flecainide Acetate	19	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Edarbi	Azilsartan Medoxomil	18	suppressed
Fosinopril Sodium	Fosinopril Sodium	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Potassium Citrate Er	Potassium Citrate	18	suppressed
Klor-Con 10	Potassium Chloride	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	11
Fluconazole	Fluconazole	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Risperidone	Risperidone	16	suppressed
Clobetasol Propionate	Clobetasol Propionate	15	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Methenamine Hippurate	Methenamine Hippurate	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Clonidine	Clonidine	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Metolazone	Metolazone	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Eplerenone	Eplerenone	13	suppressed
Estradiol (Twice Weekly)	Estradiol	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Linzess	Linaclotide	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Tramadol Hcl Er	Tramadol Hcl	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	12	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Nuplazid	Pimavanserin Tartrate	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Repatha Syringe	Evolocumab	12	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$67.01 · 3 records	Dompe US, Inc.	Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, OXERVATE, ZURZUVAE	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error